Ethyl pyruvate improves pulmonary function in mice with bleomycin-induced lung injury as monitored with hyperpolarized 129Xe MR imaging by Hodono, S. et al.
This is a repository copy of Ethyl pyruvate improves pulmonary function in mice with 
bleomycin-induced lung injury as monitored with hyperpolarized 129Xe MR imaging.




Hodono, S., Shimokawa, A., Stewart, N.J. orcid.org/0000-0001-8358-394X et al. (6 more 
authors) (2018) Ethyl pyruvate improves pulmonary function in mice with 
bleomycin-induced lung injury as monitored with hyperpolarized 129Xe MR imaging. 





This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
331Magnetic Resonance in Medical Sciences | Vol. 17, No. 4
Ethyl Pyruvate Improves Pulmonary Function in Mice  
with Bleomycin-induced Lung Injury as Monitored with  
Hyperpolarized 129Xe MR Imaging
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Renya Nishimori1, Mami Yamane1, Hirohiko Imai3, Hideaki Fujiwara1,  
and Atsuomi Kimura1*
Purpose: High Mobility Group Box1 (HMGB1), which is one of the damage-associated molecular pattern 
molecules relating to various inlammatory diseases, has gained interest as a therapeutic target because of its 
involvement in wound healing processes. In the present study, we investigated HMGB1 as a potential thera-
peutic target in a model of lung ibrosis using a preclinical hyperpolarized 129Xe (HPXe) MRI system. 
Methods: Lung injury was induced by intra-peritoneal injection of bleomycin (BLM) in 19 mice. hree 
weeks post-injection (when ibrosis was conirmed histologically), administration of ethyl pyruvate (EP) 
and alogliptin (ALG), which are down- and up-regulators of HMGB1, respectively, was commenced in six 
and seven of the 19 mice, respectively, and continued for a further 3 weeks. A separate sham-instilled group 
was formed of ive mice, which were administered with saline for 6 weeks. Over the second 3-week period, 
the efects of disease progression and pharmacological therapy in the four groups of mice were monitored 
by HPXe MRI metrics of fractional ventilation and gas-exchange function.
Results: Gas-exchange function in BLM mice was signiicantly reduced ater 3 weeks of BLM challenge com-
pared to sham-instilled mice (P < 0.05). Ethyl pyru vate was found to improve HPXe MRI metrics of both 
ventilation and gas exchange, and repair tissue damage (assessed histologically), to a similar level as sham- 
instilled mice (P < 0.05), whilst ALG treatment caused no signiicant improvement of pulmonary function.
Conclusion: his study demonstrates the down-regulator of HMGB1, EP, as a potential therapeutic agent 
for pulmonary ibrosis, as assessed by a non-invasive HPXe MRI protocol.
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affords information about gas exchange in addition to venti-
lation function. Sensitivity to gas exchange arises from the 
fact that HPXe dissolves in alveolar tissue and blood and 
exhibits a distinct chemical shift from that of gaseous-phase 
HPXe in the lung airspaces. 
We have developed a home-built continuous-low type 
Xe polarizer for production of HPXe for preclinical applica-
tions, which allows the acquisition of functional images of the 
lung from spontaneously breathing mice using a preclinical 
MRI system.3 Previously, we used this system to evaluate the 
eficacy of the drug ethyl pyruvate (EP) for treating chronic 
obstructive pulmonary disease (COPD).4 In that study, we 
suggested that High Mobility Group Box1 (HMGB1), which 
is one of the damage-associated molecular patterns (DAMPs), 
is involved in COPD disease progression.
The HMGB1 is known to play a crucial role in various 
inlammatory lung diseases, including COPD.5,6 When 
HMGB1 released from necrotic or apoptotic cells binds to its 
Introduction
In recent years, hyperpolarized (HP) noble gas MRI has been 
developed as a powerful tool for functional imaging of 
lung.1,2 In particular, hyperpolarized 129Xe (HPXe) MRI can 
be applied to a wide range of disease phenotypes since it 
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receptors, which are receptor for advanced glycation end 
(RAGE) products, and toll-like receptors (TLRs) 2 and 4, it 
activates the transcription factor nuclear factor-kappa B (NF-
せB) and mitogen-activated protein kinase (MAPK) signaling 
pathways, as shown in Fig. 1.79 Somewhat paradoxically, a 
moderate expression of HMGB1 has been shown to be linked 
to wound healing processes through the activation of extra-
cellular signal-regulated kinase (ERK) 1/2 involved in the 
MAPK pathway, while its overexpression exacerbates 
inlammation and pathology through NF-せB activation.10 
Ethyl pyruvate  has previously been reported to dose-depend-
ently activate ERK 1/2 through inhibition of HMGB1.1114 
Combining these facts with our previous observations of EP 
treatment eficacy for a murine COPD model stated above, 
we hypothesized that EP could show therapeutic eficacy for 
other lung diseases via wound healing effects by ERK 1/2 
activation, following anti-inlammatory responses by NF-せB 
down-regulation.
Pulmonary ibrosis is characterized by progressive and 
irreversible scar formation and alveolar septal wall thickening, 
which lead to severe respiratory dysfunction and ultimately 
death. Steroids and immunosuppressants have been found to 
be ineffective for improving prognosis.15 At present, two novel 
drugs, nintedanib and pirfenidone, which have shown eficacy 
for slowing the decline of lung function, are still in a regime of 
conditional recommendation against use.16 As such, preclin-
ical studies have been actively pursued in order to develop 
novel therapeutic drugs using animal models of ibrosis, such 
as bleomycin (BLM)-challenge for mice.17,18 In recent studies, 
the transforming growth factor-く1 (TGF-く1) involved in the 
Smad signaling pathway has been widely investigated as a 
potential therapeutic target.1920 However, to the best of our 
knowledge, there exist only one study reporting on the involve-
ment of HMGB1 and the effect of EP in lung ibrosis progres-
sion, in which wound healing was not investigated.11 
In the present study, we monitored the response of pul-
monary function to treatment with EP in a BLM mouse 
model of ibrosis by HPXe MRI, following the non-invasive 
preclinical MRI protocol presented in Ref. 4. Additionally, in 
order to further investigate the relationship between HMGB1 
and ERK 1/2 expression in disease and treatment processes, 
the eficacy of a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, 
alogliptin (ALG), was also monitored because ALG is known 
to down-regulates ERK 1/2 expression probably through the 
inhibition of endogenous HMGB1 protease, DPP4.21,22 The 
results were compared to support the involvement of ERK 
1/2 expression in wound healing processes. 
Methods
Animal preparation
All experimental and animal care procedures conformed to 
the guidelines of Osaka University. 
A total of 24 male, 6-week-old, ddY mice weighing 
30–35 g were purchased from Japan SLC, Inc. (Shizuoka, 
Japan). Mice were divided into four groups: 1) sham-instilled 
group (N = 5), 2) BLM-challenged group (N = 6), 3) EP-
treated group (N = 6), and 4) ALG-treated group (N = 7). To 
induce ibrotic lung injury, a 75 たL saline solution of BLM 
(1.2 U/kg body weight; Sigma-Aldrich, St Louis, MO, USA) 
was intratracheally administrated to each mouse of the BLM-
challenged, EP- and ALG-treated groups, while the sham-
instilled mice were intratracheally administered with a 75 たL 
saline solution.23 Three weeks after BLM-challenge, EP and 
ALG administration was commenced in the EP- and ALG-
treated group, respectively, following a similar protocol to 
that in Ref. 4. Briely, a 40 たL solution of EP (2.6 mg/kg body 
weight; Tokyo Chemical Industry Co., Ltd, Tokyo, Japan) or 
ALG (200 mg/kg body weight; Takeda Pharmaceutical Co., 
Ltd, Osaka, Japan) in saline was administered to each mouse 
in the EP- or ALG-treated group every weekday for an addi-
tional 3 weeks. Therefore, in total, 6 weeks were required to 
prepare the EP- and ALG-treated groups. The sham-instilled 
mice were intratracheally administered with 40 たL saline 
solution every weekday for the additional 3 week period, in 
order to ensure the same instillation process for all mice. In 
all cases, mice were anesthetized with 2% isolurane 
(ISOFLU; Sumitomo Dainippon Pharma Co. Ltd, Osaka, 
Japan) prior to instillation. The survival rates of the whole 
6-week procedure were 100%, 100%, 86%, and 100% for 
BLM-challenged, EP-treated, ALG-treated and sham-
instilled groups, respectively.
Magnetic resonance imaging
The MRI measurements of all groups were performed at 3, 4, 
5, and 6 weeks after commencement of saline or BLM 
Fig. 1 Schematic representation of the 
extra-cellular production of High Mobility 
Group Box1, its subsequent binding with 
receptors receptor for advanced glyca-
tion end  and toll-like receptors  2/4, and 
the corresponding activation of cellular 
signaling pathways. ERK, signal-regulated 
kinase; HMGB1, High Mobility Group 
Box1; MAPK, mitogen-activated protein 
kinase; NF-κB, factor-kappa B; RAGE, 
receptor for advanced glycation end; 
TLR, toll-like receptor.
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challenge (i.e., for EP- and ALG-treated groups; 0, 1, 2, and 
3 weeks from commencement of EP or ALG treatment). 
Immediately before all MR measurements, mice were anes-
thetized with 2% isolurane, and non-invasive respiratory-
gated imaging was performed without tracheal intubation.
All MRI measurements were performed on an Agilent 
Unity INOVA 400WB high-resolution NMR system 
equipped with VNMR 6.1C software (Agilent Technologies, 
Inc., Santa. Clara, CA, USA). To acquire respiratory-gated 
images from spontaneously breathing mice, the protocol 
described previously was used.4 A respiratory sensor was 
employed to synchronize the acquisition of HPXe lung 
images with inspiratory or expiratory phases. 
A home-built continuous-low type 129Xe polarizer was 
used to produce HPXe.24 A gas mixture of HPXe and N2 (Xe in 
natural abundance, 129Xe fraction 0.26: 70%, N2: 30%) was 
continuously delivered to the mouse in the MRI scanner at a 
low rate of 50 mL/min. Mice spontaneously breathed the 
polarized gas after it was mixed with O2 (low rate 9 ml/min). 
Hyperpolarized 129Xe images were acquired using a balanced 
steady-state free precession sequence modiied by adding four 
180°-pulses or two 90°-pulses in order to extract information 
about pulmonary gas-exchange or ventilation function, as 
described previously.4,25 Acquisition parameters are replicated 
here for completeness: 1000-たs Gaussian-shaped radio- 
frequency (RF) pulse of lip angle g = 40°; acquisition band-
width, 88 kHz; TR/TE = 3.6 ms/1.8 ms; echo train length, 
8; number of shots, 4; number of averages, 8; coronal slice 
thickness, 20 mm; matrix, 64 × 32 with a FOV of 80 × 25 mm2.
Pulmonary functional evaluation by HPXe MRI
Metrics of fractional ventilation, ra and xenon gas exchange 
rate, fD, of HPXe were evaluated as reported previously.4 
Only brief details are reproduced here for completeness. 
First, ra the alveolar volume fraction of gas turned over 
in a single breath, was evaluated. After gas-phase HPXe 
magnetization in the lung was destroyed by a saturation pre-
pulse, a set of inspiratory images was acquired after n 
breathing cycles. Value n was incremented from 1 to 10 in 
steps of one, and then to 12, 15, and 20; in total, 13 images 
were acquired. From these images, a ra map was obtained by 
pixel-by-pixel linear least squares itting of the signal inten-
sity as a function of n, using in-house MATLAB (The Math-
Works, Inc., Natick, MA, USA) routines. 
The xenon polarization transfer contrast (XTC) method 
was used to evaluate the parameter fD, the rate of HPXe mag-
netization diffusing from the gas-phase to dissolved-phase 
within a given exchange time.26 The XTC measurement was 
performed at the end-expiratory phase, and an fD map was 
derived by pixel-by-pixel analysis using in-house MATLAB 
routines as for ra. 
Finally, ra or fD maps were reprocessed with a 2 × 2 
median ilter, and ra or fD values were averaged over the 
whole of the lungs for each mouse. 
Histology
After HPXe MR measurements were completed, mice were 
killed with a lethal dose of carbon monoxide gas. Lungs were 
extracted, immersed in 10% formalin at 25 cmH2O and pro-
cessed for histology by staining with hematoxylin and eosin 
(H&E). Slides were evaluated to assess morphological 
changes in the lungs after 6 weeks. Coronal H&E-stained 
lung images were obtained from each mouse. Five regional 
images (right upper, middle and lower lobes, and upper and 
lower regions of the left lung, each of dimensions 175 たm × 
131.25 たm) were then captured from each coronal slide using 
a digital microscope (Celestron LCD Microscope PRO 
<CE44345>; Celestron, LLC., Torrance, CA, USA). Septal 
wall thickness, h (たm), values were calculated in the ive 
regions from four separate slices and averaged for each 
mouse. All digital images were processed using ImageJ 
(National Institutes of Health, Bethesda, MD, USA).
In order to monitor morphological changes induced 3 
weeks after BLM administration (i.e., the beginning of MRI 
measurements), an additional histological analysis group 
(HA_3w, N = 5 mice) was prepared 3 weeks post-BLM- 
challenge using the same protocol as described above. 
Statistical analysis
Statistical analysis was performed by one-way analysis of 
variance (ANOVA) with Tukey–Kramer post-hoc analysis to 
identify differences between groups. All data are presented as 
mean ± standard deviation (SD) or box-and-whisker plots, and 
differences are considered signiicant at the P < 0.05 level.
Results
Figure 2 displays representative, Fig. 2a fD and Fig. 2b ra 
maps obtained from the sham-instilled, BLM-challenged, 
EP-treated, and ALG-treated groups. Figure 3 shows longitu-
dinal changes in the group-mean values of fD and ra, respec-
tively, at 3–6 weeks post-BLM or saline challenge. The 
administration of EP and ALG was commenced at week 3, 
when a signiicant decrease of mean fD value for BLM-chal-
lenged (4.8 ± 1.0), EP-treated (fD_EP-treated = 4.8 ± 0.8) and 
ALG-treated (fD_ALG-treated = 4.8 ± 1.4) groups compared to 
that of the sham-instilled group (fD_sham-instilled = 7.4 ± 1.1) was 
observed (P < 0.05). The mean fD value of the EP-treated 
group gradually increased over the course of the treatment 
and was signiicantly larger (fD_EP-treated = 6.8 ± 0.8) than that 
of the BLM-challenged group (fD_BLM–challenged = 4.3 ± 0.9) at 
week 6 (P < 0.05), while the BLM-challenged group showed 
relatively little change in fD during the whole observation 
period. On the other hand, the mean fD values of the ALG-
treated group at weeks 5 and 6 were still signiicantly smaller 
than those of the sham-instilled group. 
The mean ra value of the EP-treated group was (ra_EP-
treated = 0.24 ± 0.02) at week 6, a signiicant improvement 
compared with week 3 (ra_EP-treated = 0.20 ± 0.02) (P < 0.05) 
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and larger than that of the BLM-challenged and ALG-treated 
groups (ra_BLM-challenged = 0.16 ± 0.03, ra_ALG-treated = 0.15 ± 0.05, 
respectively) (P < 0.05). The mean ra value of the ALG-
treated group remained low compared with the sham-instilled 
group, i.e., at a similar level to that of the BLM-challenged 
group, at weeks 4–6.
Figure 4a depicts group-mean values of the septal wall 
thickness, h, and Fig.4b representative histological results for 
all groups including the histological analysis group (HA_3w). 
The mean h value of the HA_3w group (mice killed after 3 
weeks of BLM-challenge) was hHA_3w=10.8 ± 1.7 たm, signii-
cantly larger than that of the sham-instilled mice at the same 
time-point (P < 0.05). Similarly, terminal (6-week) h values 
of BLM and ALG-treated groups (h_BLM-challenged = 10.8 ± 1.9 
たm and h_ALG-treated = 11.6 ± 1.6 たm) were larger than that of 
the sham-instilled group (h_sham-instilled = 6.4 ± 0.7 たm, 
P < 0.01), while the mean h of the EP-treated group was sig-
niicantly smaller than that of both the BLM and ALG-treated 
groups (h_EP-treated = 7.6 ± 1.0 たm, P < 0.05) and comparable 
to that of the sham-instilled group (P > 0.05). 
Figure 5 shows the correlations between MRI metrics of 
lung function and the histological h value, evaluated at week 6. 
A signiicant, positive correlation was found between ra and fD 
(P < 0.001), while negative correlations were found between h 
and fD, and h and ra (P < 0.001).
Discussion
In the present study, the temporal changes of pulmonary ven-
tilation and gas-exchange function in mice treated with EP 
and ALG as therapeutic agents for BLM-induced lung injury 
were monitored by HPXe MRI for 3 weeks, treatment com-
mencing 3 weeks post-BLM-challenge. According to 
Moeller et al,17 the eficacy of anti-ibrotic agents should be 
evaluated at least 7 days after BLM-challenge and in the 
phase of established ibrosis rather than the phase of inlam-
mation. In our measurements, week 3 was determined as the 
point where suficient symptoms of ibrosis were observed; a 
signiicant decrease of the mean fD values for the BLM- 
challenged, EP-treated and ALG-treated groups compared to 
Fig. 2 Representative parametric maps of (a) fD and (b) ra derived from longitudinal studies of mice in each of the four groups, from top to bottom: 
sham-instilled; bleomycin (BLM)-challenged; ethyl pyruvate (EP)-treated; alogliptin (ALG)-treated. In all cases, the horizontal direction shows the 
time course from the initial intra-tracheal injection of BLM or saline.
a b
Fig. 3 Box plots of the temporal change of mean (a) fD and (b) ra values for all mice, separated by group, as a function of time post-intra-
tracheal injection of bleomycin  or saline. Significant differences between groups are indicated by solid lines (*: P < 0.05). ALG, alogliptin; 
BLM, bleomycin; EP, ethyl pyruvate; IT, intra tracheal.
a b
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that of the sham-instilled group. This choice was supported by 
histological measurements of signiicantly elevated h in the 
HA_3w group. Therefore, the administration of EP was com-
menced from this time-point. However, we note one report in 
which EP treatment was investigated for 2 weeks after only 3 
days of BLM-challenge,11 thus, the choice of timing for com-
mencement of ibrosis treatment is still a matter of debate.
At week 4, both fD and ra values tended to be slightly 
lower than those at week 3; however, after week 4, both met-
rics remained approximately constant for the BLM-chal-
lenged group (i.e., the absolute values of the metrics did not 
signiicantly degrade for the remainder of the observation 
period) (fD_BLM-challenged_3w = 4.8 ± 1.0 vs. fD_BLM-challenged_6w = 
4.3 ± 0.9, ra_BLM-challenged_3w = 0.21 ± 0.04 vs. ra_BLM-challenged_6w 
= 0.16 ± 0.03). However, it should be recalled that a typical 
feature of BLM-induced lung injury is partial reversibility of 
pathology over time15; initially, ibrosis occurs following an 
acute inlammation stage with the expression of signals such 
as TGF-く1, but subsequently, the inlammatory reactions 
gradually disappear and the pathology proceeds with ibrotic 
lung remodeling.27,28 Babin et al. reported that inlammation 
in a rat model was markedly attenuated after 21 days of 
BLM-challenge.29 Therefore, our observations suggest the 
acute inlammatory reaction attenuated over time, but since 
ibrosis was already established around weeks 3–4, fD and ra 
did not change signiicantly (i.e., implying that ibrosis pre-
dominantly determines the pulmonary functional status and 
is irreversible, as expected).
The observation of a signiicant correlation of fD and ra 
values at week 6 (Fig. 5) suggests the BLM model acted to 
simultaneously impair both ventilation and gas-exchange 
function. Previously, we reported that reductions in fD and ra 
were indicative of septal wall destruction and bronchial wall 
thickening for a murine COPD model.4 In that study, the 
reduction in fD correlated with both septal wall and bronchial 
wall thicknesses, while ra correlated with bronchial wall 
thickening only. Conversely, in the present study, both met-
rics were shown to be related to septal wall thickening asso-
ciated with ibrotic lung remodeling (Fig. 5). 
Longitudinal observation of fD and ra enabled quantiica-
tion of the treatment eficacy of EP. The BLM-induced low fD 
and ra values at week 3 were recovered to a similar level as 
the sham-instilled group by 3 week’s administration of EP 
(fD_EP-treated_6w = 6.8 ± 0.8, fD_sham-instilled_6w = 7.4 ± 1.3 and 
ra_EP-treated_6w = 0.24 ± 0.02, ra_sham-instilled_6w = 0.24 ± 0.03, 
respectively). Since the administration of EP   was 
commenced after 3 weeks of BLM-challenge (i.e., after a 
 signiicant impairment of pulmonary function was observed), 
Fig. 4 (a) Box plots of the mean septal wall thickness (h) obtained from mice in each of the five groups, from left to right: sham-instilled; 
histological analysis (HA_3w), bleomycin -challenged; ethyl pyruvate-treated; alogliptin-treated. (b) Representative examples of hematox-
ylin and eosin  stained histology slides obtained from each group. ALG, alogliptin; BLM, bleomycin; EP, ethyl pyruvate.
a b
Fig. 5  Correlations between hyperpolarized 129Xe (HPXe) MRI-derived parameters of pulmonary function (ra and fD), and histology-derived 
septal wall thickness (h) obtained from the sham-instilled (), bleomycin-challenged (), ethyl pyruvate-treated (), and alogliptin-treated 
() groups after the 6-week experimental protocol. Pearson’s r values and P values of statistical significance are noted in each plot.
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we believe that the measured action of EP was indeed thera-
peutic rather than preventative against BLM-induced lung 
injury.
Ethyl pyruvate is known to down-regulate the HMGB1 
level through NF-せB inhibition, and moderately up-regulate 
ERK 1/2 expression downstream of the HMGB1/RAGE 
signaling pathway.14,30,31 Hence, the action of EP provides 
some insight into the involvement of HMGB1 and ERK 1/2 
in ibrosis development via the BLM model as shown in 
Fig. 6a. According to Ebina et al., gradual increase of 
HMGB1 expression after the inlammatory response stage 
exacerbates ibrosis.32 Ethyl pyruvate administration may 
ameliorate this ibrotic pathology by down-regulation of 
HMGB1 and up-regulation of ERK 1/2, the latter which is 
reportedly involved in tissue repair processes.10 It is also 
worth noting that Yupingfeng, a Chinese herbal remedy for 
respiratory ailments, has been found to inhibit HMGB1, 
which caused a reduction in TGF-く1 production and subse-
quently diminished collagen deposition in a BLM model of 
pulmonary ibrosis.33 
In the present study, the septal wall thickness, h, of the 
EP-treated group was found to be signiicantly smaller than 
that of the BLM-challenged group (Fig. 4). This result, com-
bined with the recovery of mean fD and ra suggests that the 
EP therapy directly acted against ibrotic tissue damage via 
ERK 1/2 activation and led to the recovery of pulmonary 
function in BLM-challenged mice. In order to further eluci-
date the involvement of ERK 1/2 in tissue repair processes, 
ALG was administered to BLM-challenged mice, since it is 
known to down-regulate ERK 1/2 (i.e., opposite to EP) prob-
ably through the inhibition of endogenous HMGB1 protease, 
DPP-4 (Fig. 6b).21,22 A positive treatment response with ALG 
was not observed; the longitudinal changes in mean fD and ra 
of the ALG-treated group showed similar tendency to those 
of the BLM-challenged group, and the h value of the ALG-
treated group was comparable to the BLM-challenged group 
and signiicantly larger than that of the sham-instilled group. 
These indings indicate that ALG did not act to repair lung 
tissue damage induced by BLM by ERK 1/2 deactivation and 
hence caused no signiicant changes in pulmonary function 
during the observation period (Fig. 3). In conclusion, we pro-
pose that the observed eficacy of EP for BLM-induced lung 
injury is mediated by regulation of HMGB1 and ERK 1/2 
expression. EP is reported to have low toxicity and to be safe 
at clinically relevant doses, and has recently been enrolled in 
preliminary clinical trials.34 As such, we believe our results 
are of particular interest to pulmonologists, and scientists and 
clinicians involved in human pulmonary MRI.
Conclusion
In the present study, the eficacy of EP and ALG treatment for 
BLM-induced lung ibrosis has been investigated by a preclin-
ical HPXe MRI protocol that can easily be applied to assess-
ment of other diseases and novel drug targets. EP treatment was 
found to improve ventilation and gas-exchange impairment 
and repair tissue damage associated with lung ibrosis, whilst 
ALG caused no signiicant change in pulmonary structure or 
function. The present results suggest that the inhibition of 
NF-せB with EP results in regulation of HMGB1 and ERK1/2 
expression, thereby leading to therapeutic eficacy. 
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